With 2.82 million shares changed hands, the volume of the stock remained heavier than its average volume of 2.24 million shares. During the session, the Drug Manufacturers – General company that operates in wider Healthcare sector, reached to the highest price of $50.0199 whereas the lowest price it dropped to was $49.65. The 52-week range on SNY shows that it touched its highest point at $58.97 and its lowest point at $45.22 during that stretch. It currently has a 1-year price target of $59.59. With its current market cap of 124.45 billion, SNY has annualized dividend of $2.04 while the current yield stands at 4.08%. Beta for the stock currently stands at 0.54.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SNY was up-trending over the past week, with a rise of 3.40%, but this was up by 2.80% over a month. Three-month performance dropped to -8.93% while six-month performance fell -0.40%. The stock lost -2.62% in the past year, while it has gained 3.40% so far this year. A look at the trailing 12-month EPS for SNY yields 1.81 with Next year EPS estimates of 4.46. For the next quarter, that number is 0.78. This implies an EPS growth rate of -9.06% for this year and 11.69% for next year. EPS is expected to grow by 8.18% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 2.68%.
Float and Shares Shorts:
At present, 2.61 billion SNY shares are outstanding with a float of 2.50 billion shares on hand for trading. On 2024-12-13, short shares totaled 3.74 million, which was 15.0 higher than short shares on 1731628800. In addition to Mr. Paul Hudson as the firm’s CEO & Director, Mr. François-Xavier Roger serves as its Executive VP & CFO.
Institutional Ownership:
Through their ownership of 0.11436 of SNY’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, SNY reported revenue of $14157000000.0 and operating income of $4089000000.0. The EBITDA in the recently reported quarter was $4701000000.0 and diluted EPS was $1.125.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for SNY since 5 analysts follow the stock currently. There are 4 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With SNY analysts setting a high price target of 67.0 and a low target of 58.94, the average target price over the next 12 months is 63.06286. Based on these targets, SNY could surge 34.35% to reach the target high and rise by 18.19% to reach the target low. Reaching the average price target will result in a growth of 26.45% from current levels.
Analysts have provided yearly estimates in a range of $4.10119 being high and $3.548 being low. For SNY, this leads to a yearly average estimate of $3.85321.
